In the past several weeks, there has been a variety of investments du jour.
Some days, the special is crypto… other times, cannabis… and sometimes, it’s Wall Street underdogs like GameStop (NYSE: GME).
But these emerging (or in some cases, fading) industries’ staying power is unproven – and what is hot today may not be hot tomorrow.
But one sector consistently delivers sky-high winners regardless of what’s “in”…
The biotech sector.
In this week’s episode of his popular YouTube series State of the Market, Chief Income Strategist Marc Lichtenfeld shines a light on this too often overlooked corner of the market where dramatic wins aren’t just possible – they’re commonplace.
Take Novavax (Nasdaq: NVAX), for example. In this week’s episode, Marc reveals how the stock soared after the company reported positive news on COVID-19.
But one-time wins aren’t the only route to wealth when it comes to biotech investing – and there’s a lot more to the biotech sector than just COVID-19 plays.
There is a wide variety of exchange-traded funds that can allow you to diversify your holdings while taking advantage of individual stocks’ success and trouncing the broader market.
You can also follow a trend or track efforts to cure a specific condition.
Marc shares his two favorite ways to play the biotech sector – one based on a powerful trend and the other based on a common catalyst – in this week’s State of the Market.
This is a sector with a strong track record of both short-term pops and long-term outperformance.
So regardless of whether you are a trend-tracking trader or a long-term investor, check out this week’s episode and consider giving the biotech sector a try.